Cytokinetics, Incorporated
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Robert I. Blum
- Full Time Employees
- 673
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 350 Oyster Point Boulevard South San Francisco CA United States of America 94080
- IPO Date
- Apr 26, 2004
- CIK
- 0001061983
- Website
- cytokinetics.com
- Similar Companies
- Business
- Cytokinetics, Incorporated (Nasdaq: CYTK) is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating cardiovascular and neuromuscular diseases in which muscle performance is compromised or declining; its lead candidate, aficamten, a next-in-class cardiac myosin inhibitor, advances in Phase 3 clinical trials for obstructive hypertrophic cardiomyopathy (oHCM, including monotherapy versus standard of care), pediatric oHCM, and non-obstructive HCM (nHCM), with additional Phase 2 development for heart failure with preserved ejection fraction (HFpEF) under the name ulacamten (CK-586); omecamtiv mecarbil, a cardiac myosin activator, progresses in Phase 3 for heart failure with reduced ejection fraction (HFrEF); the neuromuscular pipeline features CK-089, a fast skeletal muscle troponin activator, alongside additional skeletal muscle activators in research; and broader muscle biology-directed research targets energetics, growth, and metabolism of muscle. The company, founded in 1997 by pioneers in muscle biology and headquartered in South San Francisco, California, operates primarily in the United States with international partnerships extending to Greater China, Japan, and other regions through strategic alliances. Recent developments include a proposed $550 million private placement of convertible senior notes due 2031 in September 2025 to fund aficamten's potential commercial launch, expanded development, pipeline advancement, and debt refinancing; an expanded royalty financing agreement with Royalty Pharma providing up to $575 million, including $250 million upfront, to support aficamten commercialization and omecamtiv mecarbil's Phase 3 studies; and Sanofi's December 2024 acquisition of Corxel Pharmaceuticals' aficamten rights in Greater China, preserving Cytokinetics' eligibility for up to $150 million in milestones and low-to-high teen royalties on sales there.
Company News
Cytokinetics to Participate in September Investor Conferences
Can CYTK's Aficamten Strengthen Its HCM Growth Prospects?
Cytokinetics Investors Weigh Safety Data From Pivotal Trial
Cytokinetics Announces Additional Results from ACACIA-HCM and MAPLE-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology (ESC) Congress 2026
Cytokinetics, Incorporated (CYTK) Discusses Positive Phase III Results From ACACIA-HCM Trial of Aficamten in Nonobstructive HCM Transcript
Cytokinetics' Aficamten Hits Dual Phase III Endpoints in Non-Obstructive HCM
Cytokinetics eyes expanded use of heart drug after promising late-stage data
Cytokinetics Announces Positive Results from ACACIA-HCM Presented in Hot Line Session at the European Society of Cardiology (ESC) Congress 2026 and Published in The New England Journal of Medicine
Insider Transaction: Cytokinetics CEO Robert Blum Sells 7,500 Shares for $575,700
Cytokinetics Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026
Cytokinetics Gains 20.5% YTD: Buy, Sell or Hold the Stock?
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CYTK Q2 Earnings Top Estimates, Myqorzo Uptake Strong
Cytokinetics, Incorporated (CYTK) Q2 2026 Earnings Call Transcript
Cytokinetics Q2 Earnings Call Highlights
Cytokinetics (CYTK) Reports Q2 Loss, Beats Revenue Estimates
Cytokinetics wins UK approval, NICE backing for heart disease drug
Cytokinetics Announces MHRA Marketing Authorisation for MYQORZO®▼ (aficamten) and Positive Guidance from NICE for Symptomatic Obstructive Hypertrophic Cardiomyopathy in England and Wales
Cytokinetics: Label Expansion Can Turn MYQORZO Into An HCM Franchise
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)